Drug price increases have slowed, but new analysis shows launch prices pushing costs into orbit

Recent reports have demonstrated that brand-name medication prices are not increasing at the same rate as prior years. We’ve highlighted similar trends in our digging as well. While slowing list price increases can be helpful, and certainly understandable given the amount of coverage drug prices have gotten over the previous year, it misses one of the key points within the brand drug marketplace. Brand-name drug cost pressures have less and less to do with year-over-year price increases and more to do with the launch prices of new brand name medications when they initially come to market.

So naturally, we saw an opportunity for a visualization to shed some light on launch prices. This report introduces the latest visualization added to the 46brooklyn toolkit - the 46brooklyn Drug Pricing Launchpad. Spoiler alert! Brand-name drug launch prices are rising aggressively. This is a problem for sure, but why its a problem may surprise you. This report will take you on a journey through the lifecycle of a drug, and illustrate how high pre-rebate list prices on brand-name drugs today become a profit opportunity for the supply chain off generic drugs in the future.

Ben LinkOctober 15, 2019Launch, Gilead, AWP, WAC, NADAC, Zolgensma, Rebates, SCPO, Plaquenil, hydroxychloroquine

New drug pricing analysis reveals where PBMs and pharmacies make their money

For the first time in our existence, CMS has released drug pricing data that overlaps with the date of our launch. As we ripped open the data and examined CMS’ gift, we found some major changes in the way that the state of Ohio reported their data – and it has revealed some eye-opening information about PBM and pharmacy margins on prescription drugs. Given all the drug pricing noise out of Ohio, and the federal heat on PBM “spread pricing,” we decided to do a deep dive into what’s happening in Ohio, and how its new data provides incredible clues to determine where the money flows within the drug supply chain.

Ben LinkApril 21, 2019Ohio, Medicaid, spread pricing, NADAC, PBM, Abilify, Aripiprazole, Ziagen, Abacavir, Nexium, Esomeprazole, Invega, Paliperidone, Crestor, Rosuvastatin, Protopic, Tacrolimus, Plaquenil, hydroxychloroquine, Gleevec, Imatinib, Xeloda, Capecitabine, Viagra, Sildenafil, Revatio, Reyataz, Atazanavir, Valcyte, Valganciclovir, Viread, Tenofovir, CVS, Prilosec, Omeprazole, Suboxone, Buprenorphine-Naloxone